Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-CD38/BCMA CAR T lymphocytes

A preparation of T lymphocytes that have been genetically modified to express a dual-targeted chimeric antigen receptor (CAR) recognizing the tumor-associated antigens (TAAs), cluster of differentiation 38 (CD38) and B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17), with potential immunostimulating and antineoplastic activities. Upon intravenous administration, the anti-CD38/BCMA CAR T cells are directed to and induce selective toxicity in both CD38- and BCMA-expressing cells. CD38, a type II transmembrane glycoprotein, is present on various immune cells and hematologic malignancies, and its expression has been correlated with poor prognosis. BCMA is found on the surfaces of plasma cells and is and overexpressed on malignant plasma cells.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-CD38/anti-BCMA CAR T cells
anti-CD38/anti-BCMA CAR T lymphocytes
anti-CD38/BCMA CAR T cells
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search